---
layout: default
title: Ripretinib
parent: 僅模型預測 (L5)
nav_order: 863
evidence_level: L5
indication_count: 10
---

# Ripretinib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ripretinib: From Undocumented Original Indication to Multiple Endocrine Neoplasia

## One-Sentence Summary

> Ripretinib's original approved indication and mechanism of action are not documented in this evidence pack (both flagged as data gaps), and the drug currently has no market registration in Singapore.
> The TxGNN model's top prediction is **Multiple Endocrine Neoplasia**, with a raw score of 98.84% but **zero clinical trials and zero publications** supporting this specific link — the model's own rationale describes it as "score-driven only, with no supporting evidence."

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented — no original indication or Singapore license record on file |
| Predicted New Indication | Multiple Endocrine Neoplasia |
| TxGNN Prediction Score | 98.84% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Singapore Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. No original indication is recorded in this evidence pack either, so there is no basis on which to compare the drug's known pharmacology to the biology of multiple endocrine neoplasia (MEN, a RET/MEN1-driven tumour syndrome group).

The evidence pack's own rationale is explicit on this point: the mechanistic link is described as unable to be established, and the prediction is characterized as purely score-driven with no supporting clinical, literature, or mechanistic evidence.

This data-quality concern extends across the rest of the top-10 predicted indications for this candidate. Several lower-ranked entries — *infectious bovine rhinotracheitis* and *malignant catarrh* — are veterinary/reproductive-animal diseases, not human indications, and are flagged in the source data as likely knowledge-graph entity confusion. The rank-10 entry (*breast tumor luminal A or B*) returned 19 literature hits, but nearly all concern unrelated topics (B-cell immunology, hepatitis B vaccines) rather than breast cancer subtypes — consistent with a search/entity-matching artifact rather than genuine evidence. Given this pattern, the entire prediction set for this drug should be treated as low-confidence pending independent verification, not just the top-ranked candidate.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Singapore Market Information

No Singapore (HSA) market authorization is currently on file — Ripretinib is not marketed in Singapore, and no license records were provided in this evidence pack.

---

## Safety Considerations

Please refer to the package insert for safety information.

*Note: package insert warnings and contraindications data (TFDA/HSA label) were not available for this candidate — this is flagged as a **Blocking** data gap that prevents formal safety screening (S1 stage).*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top prediction (Multiple Endocrine Neoplasia) has an L5 evidence level — a TxGNN score with no supporting clinical trials, literature, or mechanistic rationale — and a Blocking data gap (missing label warnings/contraindications) prevents even a preliminary safety assessment. Several other top-10 predictions for this drug show signs of knowledge-graph entity confusion (veterinary diseases, mismatched literature topics), raising further doubt about signal quality for this candidate.

**To proceed, the following is needed:**
- Obtain Ripretinib's package insert warnings and contraindications (TFDA/HSA) — currently Blocking (DG001)
- Obtain Ripretinib's mechanism of action from DrugBank to enable mechanistic plausibility review (DG002)
- Confirm the original approved indication(s) for Ripretinib, currently missing from this evidence pack
- Run a targeted clinical trial and literature search specific to "Ripretinib" + "multiple endocrine neoplasia" (or RET/MEN1 pathway) to establish whether any real evidence base exists
- Audit knowledge-graph entity mapping for this candidate given the veterinary-disease and topic-mismatch literature noise observed in ranks 2–10
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

